Anesiva says local anesthetic trial gets positive results
Dec 26 (Reuters) - Par Pharmaceutical Cos. Inc. (PRX.N) said it got U.S. regulatory approval for the generic version of GlaxoSmithKline Plc's (GSK.L) Zofran tablets, used for the prevention of chemotherapy-related nausea and vomiting.
The approval is for ondansetron orally disintegrating tablets in 4 mg and 8 mg strengths, the company said.
Barr Pharmaceuticals Inc.'s BRL.N Pliva Inc. subsidiary will have exclusive rights to market, sell and distribute the tablets in the United States, Par Pharma said.
(Reporting by Shikhar Balwani in Bangalore)
((Editing by Anil Kumar; Reuters Messaging: shikhar.balwani.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: PARPHARMACEUTICAL FDA/
(C) Reuters 2006. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS6425
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters